Volume 19 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(11): 1823-1826, 1839
ZHANG Hui-hui, WANG Bei-bei, ZHANG Xian-wen, WANG Li-hua, WEI Li, LI Yan, ZHANG Jing. Treatment effect and analysis of prognostic factors of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for advanced cervical cancer with pelvic lymph node metastasis[J]. Chinese Journal of General Practice, 2021, 19(11): 1823-1826, 1839. doi: 10.16766/j.cnki.issn.1674-4152.002176
Citation: ZHANG Hui-hui, WANG Bei-bei, ZHANG Xian-wen, WANG Li-hua, WEI Li, LI Yan, ZHANG Jing. Treatment effect and analysis of prognostic factors of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for advanced cervical cancer with pelvic lymph node metastasis[J]. Chinese Journal of General Practice, 2021, 19(11): 1823-1826, 1839. doi: 10.16766/j.cnki.issn.1674-4152.002176
shu

Treatment effect and analysis of prognostic factors of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for advanced cervical cancer with pelvic lymph node metastasis

doi: 10.16766/j.cnki.issn.1674-4152.002176
  • 1.

    Department of Gynecological Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0384

  • Received Date: 2021-05-22
    Available Online: 2022-02-15
    Abstract
  •   Objective   To evaluate the efficacy and prognostic factors of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy of advanced cervical cancer patients with pelvic lymph node metastasis.   Methods   A total of 67 cases of advanced cervical cancer patients with pelvic lymph node metastasis (ⅡA - ⅢB) were collected in our hospital from January 2015 to January 2018. They were assigned to two groups: the treatment group (n=27) was treated with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy and consolidation chemotherapy, whilst the control group (n=40) only received concurrent chemoradiotherapy and consolidation chemotherapy. The clinical effect and related prognostic factors were observed. The survival curve was established via the Kaplan-Meier method. The survival of the two groups was compared via log-rank test. Multivariate Cox regression analysis was used for multivariate analysis.   Results   Compared with the control group, the treatment group showed improved objective response rate (88.9% vs. 67.5%, P < 0.05) and 3-year progression-free survival (PFS) rate (70.4% vs. 45.0%, P < 0.05). No significant difference was observed in the 3-year overall survival (OS) rate between the two groups (77.8% vs. 65.0%, P>0.05). Bone marrow inhibition, gastrointestinal reactions and urinary system reactions were not significantly different in both groups (all P>0.05). Multivariate analysis showed that FIGO stage and location of lymph node metastasis were independent prognostic factors of OS. FIGO stage, location of lymph node metastasis and neoadjuvant chemotherapy were independent prognostic factors of PFS.   Conclusion   The addition of neoadjuvant chemotherapy to concurrent chemoradiotherapy and consolidation chemotherapy is superior to concurrent chemoradiotherapy and consolidation chemotherapy for advanced cervical cancer with pelvic lymph node metastasis. Moreover, the adverse reactions can be tolerated.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
    [2]
    TORRE L A, ISLAMI F, SIEGEL R L, et al. Global cancer in women: Burden and trends[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 444-457. doi: 10.1158/1055-9965.EPI-16-0858
    [3]
    MANDERS D B, MORON A, MCINTIRE D, et al. Locally advanced cervical cancer outcomes with variable adherence to treatment[J]. Am J Clin Oncol, 2018, 41(5): 447-451. doi: 10.1097/COC.0000000000000300
    [4]
    CIBULA D, POTTER R, PLANCHAMPY F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer[J]. Radiother Oncol, 2018, 127(3): 404-416. doi: 10.1016/j.radonc.2018.03.003
    [5]
    ABU-RUSTUM N R, YASHAR C M, BEAN S, et al. NCCN guidelines insights: Cervical cancer, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(6): 660-666. doi: 10.6004/jnccn.2020.0027
    [6]
    MARTH C, LANDONI F, MAHNER S, et al. ESMO guidelines committee. cervical cancer_ ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl 4): iv72-iv83.
    [7]
    MAHANTSHETTY U, KRISHNATRY R, HANDE V, et al. Magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer: An experience from a tertiary cancer center in a low and middle income countries setting[J]. Int J Radiat Oncol Biol Phys, 2017, 99(3): 608-617. doi: 10.1016/j.ijrobp.2017.06.010
    [8]
    KILIC C, KIMYON C G, CAKIR C, et al. Recurrence pattern and prognostic factors for survival in cervical cancer with lymph node metastasis[J]. J Obstet Gynaecol Res, 2021, 47(6): 2175-2184. doi: 10.1111/jog.14762
    [9]
    JURGENLIEMK-SCHULZ I M, BERIWAL S, DELEEUW A A C, et al. Management of nodal disease in advanced cervical cancer[J]. Semin Radiat Oncol, 2019, 29(2): 158-165. doi: 10.1016/j.semradonc.2018.11.002
    [10]
    LIN A J, DEHDASHTI F, MASSAD L S, et al. Long-term outcomes of cervical cancer patients treated with definitive chemoradiation following a complete metabolic response[J]. Clin Oncol(R Coll Radiol), 2021, 33(5): 300-306. doi: 10.1016/j.clon.2021.01.010
    [11]
    PARK S H, CHEON H, CHONG G O, et al. Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer[J]. Gynecol Oncol, 2018, 148(3): 449-455. doi: 10.1016/j.ygyno.2018.01.005
    [12]
    CHUNG H H, CHEON G J, KANG K W, et al. Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41(4): 674-681. doi: 10.1007/s00259-013-2626-1
    [13]
    SANT M, CHIRLAQUELOPEZ M D, AGRESTI R, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE- 5 study[J]. Eur J Cancer, 2015, 51(15): 2191-2205. doi: 10.1016/j.ejca.2015.07.022
    [14]
    田鲜艳, 李荣岗, 刘冬英, 等. 新辅助化疗联合同步放化疗治疗48例局部晚期宫颈癌疗效分析[J]. 广东医学院学报, 2017, 35(3): 312-314. doi: 10.3969/j.issn.1005-4057.2017.03.027
    [15]
    BENSON R, PATHY S, KUMAR L, et al. Locally advanced cervical cancer - neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: A phase Ⅱ study[J]. J Cancer Res Ther, 2019, 15(6): 1359-1364. doi: 10.4103/jcrt.JCRT_39_18
    [16]
    张达. 单纯放疗、新辅助化疗及同步放化疗治疗宫颈癌临床近期疗效比较[J]. 中华肿瘤防治杂志, 2016, 23(S2): 256-257. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL2016S2124.htm
    [17]
    刘淑荣, 廖革望. 局部晚期宫颈癌化疗联合放疗最佳模式探讨[J]. 中华肿瘤防治杂志, 2017, 24(3): 196-200. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201703011.htm
    [18]
    何惠兰, 史惠蓉, 贾艳艳. 紫杉醇与顺铂新辅助化疗联合同步放化疗治疗局部晚期宫颈鳞状细胞癌患者的疗效观察[J]. 癌症进展, 2019, 17(17): 2038-2040. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201917014.htm
    [19]
    李娜, 李辉, 马春雨, 等. 紫杉醇联合顺铂新辅助化疗与同步放化疗在局部晚期宫颈癌中的疗效评价[J]. 中国妇产科临床杂志, 2019, 20(3): 41-43. https://www.cnki.com.cn/Article/CJFDTOTAL-FKLC201903013.htm
    [20]
    陆婕, 吴晓杰, 朱巍立. 根治性宫颈癌手术患者盆腔淋巴结转移和预后的影响因素分析[J]. 中华全科医学, 2017, 15(2): 270-273. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201702027.htm
    [21]
    SHIMOJI Y, NAGAI Y, TOITA T, et al. A phase Ⅱ study of neoadjuvant chemotherapy followed by extended field concurrent chemoradiotherapy for para-aortic lymph node positive cervical cancer[J]. Anticancer Res, 2020, 40(6): 3565-3570. doi: 10.21873/anticanres.14346
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (224) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return